Matthew H Forsberg
Overview
Explore the profile of Matthew H Forsberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shankar K, Zingler-Hoslet I, Tabima D, Zima S, Shi L, Gimse K, et al.
Mol Ther
. 2025 Jan;
33(3):1014-1030.
PMID: 39815622
Natural killer (NK) cells are an appealing off-the-shelf, allogeneic cellular therapy due to their cytotoxic profile. However, their activity against solid tumors remains suboptimal in part due to the upregulation...
2.
Cappabianca D, Pham D, Forsberg M, Bugel M, Tommasi A, Lauer A, et al.
Mol Ther Methods Clin Dev
. 2024 May;
32(2):101249.
PMID: 38699288
Manufacturing chimeric antigen receptor (CAR) T cell therapies is complex, with limited understanding of how medium composition impacts T cell phenotypes. CRISPR-Cas9 ribonucleoproteins can precisely insert a CAR sequence while...
3.
Cappabianca D, Pham D, Forsberg M, Bugel M, Tommasi A, Lauer A, et al.
bioRxiv
. 2024 Apr;
PMID: 38562720
Manufacturing Chimeric Antigen Receptor (CAR) T cell therapies is complex, with limited understanding of how media composition impact T-cell phenotypes. CRISPR/Cas9 ribonucleoproteins can precisely insert a CAR sequence while disrupting...
4.
Kink J, Bellio M, Forsberg M, Lobo A, Thickens A, Lewis B, et al.
Stem Cell Res Ther
. 2024 Mar;
15(1):72.
PMID: 38475968
Background: Hematopoietic acute radiation syndrome (H-ARS) occurring after exposure to ionizing radiation damages bone marrow causing cytopenias, increasing susceptibility to infections and death. We and others have shown that cellular...
5.
Sodji Q, Forsberg M, Cappabianca D, Kerr C, Sarko L, Shea A, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201618
Chimeric antigen receptor (CAR) T cells have been relatively ineffective against solid tumors. Low-dose radiation which can be delivered to multiple sites of metastases by targeted radionuclide therapy (TRT) can...
6.
Ayuso J, Farooqui M, Virumbrales-Munoz M, Denecke K, Rehman S, Schmitz R, et al.
Nat Commun
. 2023 Nov;
14(1):7292.
PMID: 37949872
No abstract available.
7.
Ayuso J, Farooqui M, Virumbrales-Munoz M, Denecke K, Rehman S, Schmitz R, et al.
Nat Commun
. 2023 Oct;
14(1):6681.
PMID: 37865647
Numerous studies are exploring the use of cell adoptive therapies to treat hematological malignancies as well as solid tumors. However, there are numerous factors that dampen the immune response, including...
8.
Schmitz R, Tweed K, Rehani P, Samimi K, Riendeau J, Jones I, et al.
bioRxiv
. 2023 Feb;
PMID: 36747690
New non-destructive tools are needed to reliably assess lymphocyte function for immune profiling and adoptive cell therapy. Optical metabolic imaging (OMI) is a label-free method that measures the autofluorescence intensity...
9.
Zhang J, Webster S, Duffin B, Bernstein M, Steill J, Swanson S, et al.
Stem Cell Reports
. 2023 Jan;
18(2):585-596.
PMID: 36638788
Macrophages armed with chimeric antigen receptors (CARs) provide a potent new option for treating solid tumors. However, genetic engineering and scalable production of somatic macrophages remains significant challenges. Here, we...
10.
Mueller K, Piscopo N, Forsberg M, Saraspe L, Das A, Russell B, et al.
J Immunother Cancer
. 2022 Nov;
10(9).
PMID: 36382633
Background: Chimeric antigen receptor (CAR) T cells have demonstrated high clinical response rates against hematological malignancies (e.g., CD19+ cancers) but have shown limited activity in patients with solid tumors. Recent...